Randomised controlled trial of prophylactic antibiotics before insertion of intrauterine devices

Lancet

Volumn 351, Issue 9108, 1998, Pages 1005-1008

  Walsh, Terri ^a   Grimes, David ^b   Frezieres, Ron ^a   Nelson, Anita ^c   Bernstein, Leslie ^d   Coulson, Anne ^e   Bernstein, Gerald ^d  

^a California Family Health Council   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c HARBOR UCLA MEDICAL CENTER   (United States)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; PLACEBO;

ADULT; ANTIBIOTIC PROPHYLAXIS; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; INTRAUTERINE CONTRACEPTIVE DEVICE; METRITIS; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCREENING;

EID: 0032481859     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(97)09086-7     Document Type: Article

References (17)

1. Kooiker CH, Scutchfield FD Barriers to prescribing the Copper T 380A intrauterine device by physicians. West J Med. 153:1990;279-282.
2. World Health Organization. Mechanism of action, safety and efficacy of intrauterine devices. Technical Report Series 753. Geneva: WHO, 1987.
3. Farley TMM, Rosenberg MJ, Rowe P, Chen J-H, Meirik O Intrauterine devices and pelvic inflammatory disease: an international perspective. Lancet. 339:1992;785-788.
4. Lee NC, Rubin GL, Ory HW, Burkman RT Type of intrauterine device and the risk of pelvic inflammatory disease. Obstet Gynecol. 62:1983;1-6.
5. Mishell DR Jr., Bell JH, Good RG, Moyer DL The intrauterine device: a bacteriologic study of the endometrial cavity. Am J Obstet Gynecol. 96:1966;119-126.
6. Tietze C, Lewit S Evaluation of intrauterine devices: ninth progress report of the Cooperative Statistical Program. Stud Fam Plann. 55:1970;1-40.
7. Rivera R. Is there an effect of the IUD string in the development of pelvic inflammatory disease in IUD users? In: Bardin CW, Mishell DR Jr, eds. Proceedings from the Fourth International Conference on IUDs. Butterworth-Heinemann, 1994; 171-78.
8. Sawaya GF, Grady D, Kerlikowske K, Grimes DA Antibiotics at the time of induced abortion: the case for universal prophylaxis based on a meta-analysis. Obstet Gynecol. 87:1996;884-890.
9. Sinei SKA, Schulz KF, Lamptey PRet al. Preventing IUD related pelvic infection; the efficacy of prophylactic doxycycline at insertion. Br J Obstet Gynaecol. 97:1990;412-419.
10. Ladipo OA, Farr G, Otolorin Eet al. Prevention of IUD-related pelvic infection: the efficacy of prophylactic doxycycline at IUD insertion. Adv Contracept. 7:1991;43-54.
11. Walsh TL, Bernstein GS, Grimes DAet al. Effect of prophylactic antibiotics on morbidity associated with IUD insertion: results of a pilot randomized controlled trial. Contraception. 50:1994;319-327.
12. United States Pharmacopeial Convention, Inc. Drug information for the health care professional, 17th edn. Rockville, MD: United States Pharmacopeial Convention, Inc, 1997: 487-89.
13. American Medical Association. AMA Drug Evaluations Annual 1995. Chicago: American Medical Association, 1995: 1507-08.
14. Hager WD, Eschenbach DA, Spence MR, Sweet RL Criteria for diagnosis and grading of salpingitis. Obstet Gynecol. 61:1983;113.
15. Sivin I, Mahgoub SE, McCarthy Tet al. Long-term contraception with the levonorgestrel 20 mcg/day (LNg 20) and the Copper T 380A intrauterine devices: a five-year randomized study. Contraception. 42:1990;361-378.
16. Indian Council of Medical Research, Task Force on IUDs. Randomized clinical trials with intrauterine devices (levonorgestrel intrauterine device, LNG), Cu T 380Ag, Cu T 220C, Cu T 200B: a 36-month study. Contraception 1989: 39: 37-52.
17. Schulz KF, Chalmers I, Hayes RJ, Altman DG Empirical evidence of bias: dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA. 273:1995;408-412.